$67.3 Million is the total value of KCK LTD.'s 3 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| Sell | SIGHT SCIENCES INC | $41,214,012 | -29.3% | 4,715,562 | -1.3% | 61.22% | -29.9% | |
| NPCE | NEUROPACE INC | $26,081,955 | +211.4% | 5,621,111 | 0.0% | 38.74% | +208.7% | |
| AILERON THERAPEUTICS INC | $27,703 | -47.7% | 22,341 | 0.0% | 0.04% | -48.1% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-05
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| SIGHT SCIENCES, INC. | 8 | Q3 2023 | 87.4% |
| NEUROPACE, INC. | 8 | Q3 2023 | 77.7% |
| AILERON THERAPEUTICS, INC. | 4 | Q3 2022 | 0.3% |
| AILERON THERAPEUTICS INC | 4 | Q3 2023 | 0.1% |
| IMMUNIC, INC. | 3 | Q2 2022 | 0.8% |
View KCK LTD.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| VITAL THERAPIES INC | February 13, 2017 | 2,788,181 | 8.7% |
View KCK LTD.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 4 | 2023-12-01 |
| 144 | 2023-11-29 |
| 4 | 2023-11-29 |
| 13F-HR | 2023-11-01 |
| 13F-HR | 2023-07-25 |
| 13F-HR | 2023-05-05 |
| SC 13G | 2023-02-13 |
| 13F-HR | 2023-01-31 |
View KCK LTD.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.